Literature DB >> 18158740

Antibody to dengue 1 detected more than 60 years after infection.

Allison Imrie1, Janet Meeks, Alexandra Gurary, Munkhzul Sukhbaatar, Thang Thua Truong, C Bruce Cropp, Paul Effler.   

Abstract

We investigated the duration of humoral responses to dengue virus infection in individuals who recalled experiencing dengue fever-like illnesses at the time of the Second World War, when dengue fever epidemics occurred throughout the Pacific and Southeast Asia. In July 1943 dengue fever reappeared in Hawaii following an interval of 31 years. Over the next 12 months a total of 1498 locally transmitted cases were reported, and at least 46 imported cases were identified, most of which were among members of the military returning from the Pacific Theatre of the war. Serum samples collected in 2005, more than 60 years after onset of symptoms, were tested for the presence of dengue-specific antibodies using a rapid ELISA test, and by plaque reduction neutralization test. Four of seven samples were positive for dengue-specific IgG and demonstrated neutralization titers >or=160 to dengue 1. We describe the existence of dengue-specific antibodies in the serum of people infected more than 60 years earlier.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18158740      PMCID: PMC3084288          DOI: 10.1089/vim.2007.0050

Source DB:  PubMed          Journal:  Viral Immunol        ISSN: 0882-8245            Impact factor:   2.257


  18 in total

Review 1.  Dengue: an update.

Authors:  María G Guzmán; Gustavo Kourí
Journal:  Lancet Infect Dis       Date:  2002-01       Impact factor: 25.071

2.  Cutting edge: long-term B cell memory in humans after smallpox vaccination.

Authors:  Shane Crotty; Phil Felgner; Huw Davies; John Glidewell; Luis Villarreal; Rafi Ahmed
Journal:  J Immunol       Date:  2003-11-15       Impact factor: 5.422

3.  Control of dengue in Hawaii.

Authors:  C L WILBAR
Journal:  Am J Public Health Nations Health       Date:  1947-06

4.  Dengue virus identification by the plaque reduction neutralization test.

Authors:  P K Russell; A Nisalak
Journal:  J Immunol       Date:  1967-08       Impact factor: 5.422

5.  Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine.

Authors:  J D Poland; C H Calisher; T P Monath; W G Downs; K Murphy
Journal:  Bull World Health Organ       Date:  1981       Impact factor: 9.408

Review 6.  Dengue/dengue haemorrhagic fever: history and current status.

Authors:  Duane J Gubler
Journal:  Novartis Found Symp       Date:  2006

7.  Dengue in Greece in 1927 and 1928 and the pathogenesis of dengue hemorrhagic fever: new data and a different conclusion.

Authors:  L Rosen
Journal:  Am J Trop Med Hyg       Date:  1986-05       Impact factor: 2.345

Review 8.  Pathogenesis of dengue: challenges to molecular biology.

Authors:  S B Halstead
Journal:  Science       Date:  1988-01-29       Impact factor: 47.728

9.  Etiologies of the experimental dengues of Siler and Simmons.

Authors:  S B Halstead
Journal:  Am J Trop Med Hyg       Date:  1974-09       Impact factor: 2.345

10.  Dengue fever, Hawaii, 2001-2002.

Authors:  Paul V Effler; Lorrin Pang; Paul Kitsutani; Vance Vorndam; Michele Nakata; Tracy Ayers; Joe Elm; Tammy Tom; Paul Reiter; José G Rigau-Perez; John M Hayes; Kristin Mills; Mike Napier; Gary G Clark; Duane J Gubler
Journal:  Emerg Infect Dis       Date:  2005-05       Impact factor: 6.883

View more
  48 in total

1.  Homology of complete genome sequences for dengue virus type-1, from dengue-fever- and dengue-haemorrhagic-fever-associated epidemics in Hawaii and French Polynesia.

Authors:  A Imrie; C Roche; Z Zhao; S Bennett; M Laille; P Effler; V-M Cao-Lormeau
Journal:  Ann Trop Med Parasitol       Date:  2010-04

Review 2.  Emergence of the severe syndrome and mortality associated with dengue and dengue-like illness: historical records (1890 to 1950) and their compatibility with current hypotheses on the shift of disease manifestation.

Authors:  Goro Kuno
Journal:  Clin Microbiol Rev       Date:  2009-04       Impact factor: 26.132

3.  Delineating antibody recognition against Zika virus during natural infection.

Authors:  Lei Yu; Ruoke Wang; Fei Gao; Min Li; Jianying Liu; Jian Wang; Wenxin Hong; Lingzhai Zhao; Yingfen Wen; Chibiao Yin; Hua Wang; Qi Zhang; Yangyang Li; Panpan Zhou; Rudian Zhang; Yang Liu; Xiaoping Tang; Yongjun Guan; Cheng-Feng Qin; Ling Chen; Xuanling Shi; Xia Jin; Gong Cheng; Fuchun Zhang; Linqi Zhang
Journal:  JCI Insight       Date:  2017-06-15

4.  Complexity of Neutralizing Antibodies against Multiple Dengue Virus Serotypes after Heterotypic Immunization and Secondary Infection Revealed by In-Depth Analysis of Cross-Reactive Antibodies.

Authors:  Wen-Yang Tsai; Anna Durbin; Jih-Jin Tsai; Szu-Chia Hsieh; Stephen Whitehead; Wei-Kung Wang
Journal:  J Virol       Date:  2015-07       Impact factor: 5.103

5.  Original antigenic sin in dengue revisited.

Authors:  Simona Zompi; Eva Harris
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-16       Impact factor: 11.205

6.  Heterotypic dengue infection with live attenuated monotypic dengue virus vaccines: implications for vaccination of populations in areas where dengue is endemic.

Authors:  Anna P Durbin; Alexander Schmidt; Dan Elwood; Kimberli A Wanionek; Janece Lovchik; Bhavin Thumar; Brian R Murphy; Stephen S Whitehead
Journal:  J Infect Dis       Date:  2010-12-14       Impact factor: 5.226

7.  CD8+ T Cells Can Mediate Short-Term Protection against Heterotypic Dengue Virus Reinfection in Mice.

Authors:  Raphaël M Zellweger; William W Tang; William E Eddy; Kevin King; Marisa C Sanchez; Sujan Shresta
Journal:  J Virol       Date:  2015-04-08       Impact factor: 5.103

8.  A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial.

Authors:  Anna P Durbin; Beth D Kirkpatrick; Kristen K Pierce; Daniel Elwood; Catherine J Larsson; Janet C Lindow; Cecilia Tibery; Beulah P Sabundayo; Donna Shaffer; Kawsar R Talaat; Noreen A Hynes; Kimberli Wanionek; Marya P Carmolli; Catherine J Luke; Brian R Murphy; Kanta Subbarao; Stephen S Whitehead
Journal:  J Infect Dis       Date:  2013-01-17       Impact factor: 5.226

9.  Natural strain variation and antibody neutralization of dengue serotype 3 viruses.

Authors:  Wahala M P B Wahala; Eric F Donaldson; Ruklanthi de Alwis; Mary Ann Accavitti-Loper; Ralph S Baric; Aravinda M de Silva
Journal:  PLoS Pathog       Date:  2010-03-19       Impact factor: 6.823

10.  Phase 1 trial of the dengue virus type 4 vaccine candidate rDEN4{Delta}30-4995 in healthy adult volunteers.

Authors:  Peter F Wright; Anna P Durbin; Stephen S Whitehead; Mine R Ikizler; Susan Henderson; Joseph E Blaney; Bhavin Thumar; Sharon Ankrah; Michael T Rock; Brett A McKinney; Brian R Murphy; Alexander C Schmidt
Journal:  Am J Trop Med Hyg       Date:  2009-11       Impact factor: 2.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.